Research programme: cancer vaccines - Sanofi/PDL BioPharma
Alternative Names: Cancer vaccines research programme - sanofi/Protein Design LabsLatest Information Update: 08 Apr 2022
Price :
$50 *
At a glance
- Originator sanofi pasteur
- Developer Sanofi
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 30 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form Sanofi-Aventis